These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7565622)

  • 1. Structure-activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand-receptor binding.
    Daniels AJ; Matthews JE; Viveros OH; Leban JJ; Cory M; Heyer D
    Mol Pharmacol; 1995 Sep; 48(3):425-32. PubMed ID: 7565622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors.
    Martel JC; Fournier A; St-Pierre S; Dumont Y; Forest M; Quirion R
    Mol Pharmacol; 1990 Oct; 38(4):494-502. PubMed ID: 2172766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
    Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
    J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
    Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
    Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
    Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression cloning of a human brain neuropeptide Y Y2 receptor.
    Gehlert DR; Beavers LS; Johnson D; Gackenheimer SL; Schober DA; Gadski RA
    Mol Pharmacol; 1996 Feb; 49(2):224-8. PubMed ID: 8632753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
    Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
    J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
    Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
    Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G
    Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system.
    Lindner D; van Dieck J; Merten N; Mörl K; Günther R; Hofmann HJ; Beck-Sickinger AG
    Biochemistry; 2008 Jun; 47(22):5905-14. PubMed ID: 18457425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of alpha-helix in C-terminal fragments of neuropeptide Y.
    Yumoto N; Murase S; Hattori T; Yamamoto H; Tatsu Y; Yoshikawa S
    Biochem Biophys Res Commun; 1993 Nov; 196(3):1490-5. PubMed ID: 8250906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
    Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
    J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
    Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
    J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor.
    Gehlert DR; Schober DA; Beavers L; Gadski R; Hoffman JA; Smiley DL; Chance RE; Lundell I; Larhammar D
    Mol Pharmacol; 1996 Jul; 50(1):112-8. PubMed ID: 8700103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
    Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
    J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C; Beck-Sickinger AG
    J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-affinity neuropeptide Y receptor antagonists.
    Daniels AJ; Matthews JE; Slepetis RJ; Jansen M; Viveros OH; Tadepalli A; Harrington W; Heyer D; Landavazo A; Leban JJ; Spaltenstein A
    Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9067-71. PubMed ID: 7568074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strongly altered receptor binding properties in PP and NPY chimeras are accompanied by changes in structure and membrane binding.
    Lerch M; Kamimori H; Folkers G; Aguilar MI; Beck-Sickinger AG; Zerbe O
    Biochemistry; 2005 Jun; 44(25):9255-64. PubMed ID: 15966750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
    Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.